267 related articles for article (PubMed ID: 29691340)
1. Extensive Gene Amplification as a Mechanism for Piperacillin-Tazobactam Resistance in Escherichia coli.
Schechter LM; Creely DP; Garner CD; Shortridge D; Nguyen H; Chen L; Hanson BM; Sodergren E; Weinstock GM; Dunne WM; van Belkum A; Leopold SR
mBio; 2018 Apr; 9(2):. PubMed ID: 29691340
[TBL] [Abstract][Full Text] [Related]
2. Semirapid Detection of Piperacillin/Tazobactam Resistance and Extended-Spectrum Resistance to β-Lactams/β-Lactamase Inhibitors in Clinical Isolates of Escherichia coli.
Rodríguez-Villodres Á; Gutiérrez Linares A; Gálvez-Benitez L; Pachón J; Lepe JA; Smani Y
Microbiol Spectr; 2021 Oct; 9(2):e0080121. PubMed ID: 34668721
[TBL] [Abstract][Full Text] [Related]
3. Resistance to piperacillin/tazobactam in Escherichia coli resulting from extensive IS26-associated gene amplification of blaTEM-1.
Hansen KH; Andreasen MR; Pedersen MS; Westh H; Jelsbak L; Schønning K
J Antimicrob Chemother; 2019 Nov; 74(11):3179-3183. PubMed ID: 31411684
[TBL] [Abstract][Full Text] [Related]
4. Contribution of β-lactamase and efflux pump overproduction to tazobactam-piperacillin resistance in clinical isolates of Escherichia coli.
Suzuki Y; Sato T; Fukushima Y; Nakajima C; Suzuki Y; Takahashi S; Yokota SI
Int J Antimicrob Agents; 2020 Apr; 55(4):105919. PubMed ID: 32062000
[TBL] [Abstract][Full Text] [Related]
5. Piperacillin/tazobactam resistance in a clinical isolate of Escherichia coli due to IS26-mediated amplification of bla
Hubbard ATM; Mason J; Roberts P; Parry CM; Corless C; van Aartsen J; Howard A; Bulgasim I; Fraser AJ; Adams ER; Roberts AP; Edwards T
Nat Commun; 2020 Oct; 11(1):4915. PubMed ID: 33004811
[TBL] [Abstract][Full Text] [Related]
6. Piperacillin-Tazobactam-Resistant/Third-Generation Cephalosporin-Susceptible Escherichia coli and Klebsiella pneumoniae Isolates: Resistance Mechanisms and In vitro-In vivo Discordance.
Abdelraouf K; Chavda KD; Satlin MJ; Jenkins SG; Kreiswirth BN; Nicolau DP
Int J Antimicrob Agents; 2020 Mar; 55(3):105885. PubMed ID: 31923568
[TBL] [Abstract][Full Text] [Related]
7. Extended-spectrum resistance to β-lactams/β-lactamase inhibitors (ESRI) evolved from low-level resistant Escherichia coli.
Rodríguez-Villodres Á; Gil-Marqués ML; Álvarez-Marín R; Bonnin RA; Pachón-Ibáñez ME; Aguilar-Guisado M; Naas T; Aznar J; Pachón J; Lepe JA; Smani Y
J Antimicrob Chemother; 2020 Jan; 75(1):77-85. PubMed ID: 31613964
[TBL] [Abstract][Full Text] [Related]
8. Diminished Susceptibility to Cefoperazone/Sulbactam and Piperacillin/Tazobactam in
Yang F; Zhao Q; Wang L; Wu J; Jiang L; Sheng L; Zhang L; Xue Z; Yi M
Pol J Microbiol; 2022 Jun; 71(2):251-256. PubMed ID: 35716168
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of piperacillin-tazobactam and cefotaxime against Escherichia coli hyperproducing TEM-1 in a mouse peritonitis infection model.
Hertz FB; Andreasen MR; Almind SR; Nielsen KL; Hansen KH; Jelsbak L; Frimodt-Møller N; Schønning K
Int J Antimicrob Agents; 2022 Apr; 59(4):106543. PubMed ID: 35134504
[TBL] [Abstract][Full Text] [Related]
10. Detection of Escherichia coli and associated β-lactamases genes from diabetic foot ulcers by multiplex PCR and molecular modeling and docking of SHV-1, TEM-1, and OXA-1 β-lactamases with clindamycin and piperacillin-tazobactam.
Shahi SK; Singh VK; Kumar A
PLoS One; 2013; 8(7):e68234. PubMed ID: 23861873
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamic evaluation of piperacillin/tazobactam against extended-spectrum β-lactamase (ESBL)-producing versus non-ESBL-producing Escherichia coli in a hollow-fibre infection model.
Islam K; Sime FB; Bauer MJ; Forde BM; Wallis SC; Harris P; Naicker S; Shirin T; Habib ZH; Flora MS; Roberts JA
Int J Antimicrob Agents; 2022 Aug; 60(2):106623. PubMed ID: 35728714
[TBL] [Abstract][Full Text] [Related]
12. Piperacillin/tazobactam-resistant, cephalosporin-susceptible
Edwards T; Heinz E; van Aartsen J; Howard A; Roberts P; Corless C; Fraser AJ; Williams CT; Bulgasim I; Cuevas LE; Parry CM; Roberts AP; Adams ER; Mason J; Hubbard ATM
Microb Genom; 2022 Apr; 8(4):. PubMed ID: 35404783
[TBL] [Abstract][Full Text] [Related]
13. Role of bla
Gálvez-Benítez L; de la Rosa JMO; Rodriguez-Villodres A; Casimiro-Soriguer CS; Molina-Panadero I; Alvarez-Marin R; Bonnin RA; Naas T; Pachón J; Cisneros JM; Lepe JA; Smani Y
J Infect; 2023 Sep; 87(3):220-229. PubMed ID: 37442373
[TBL] [Abstract][Full Text] [Related]
14. Point mutations in the inc antisense RNA gene are associated with increased plasmid copy number, expression of blaCMY-2 and resistance to piperacillin/tazobactam in Escherichia coli.
Kurpiel PM; Hanson ND
J Antimicrob Chemother; 2012 Feb; 67(2):339-45. PubMed ID: 22117029
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the Treatment Outcome of Piperacillin-Tazobactam versus Carbapenems for Patients with Bacteremia Caused by Extended-Spectrum β-Lactamase-Producing Escherichia coli in Areas with Low Frequency of Coproduction of OXA-1: a Preliminary Analysis.
Hoashi K; Hayama B; Suzuki M; Sakurai A; Takehana K; Enokida T; Takeda K; Ohkushi D; Doi Y; Harada S
Microbiol Spectr; 2022 Aug; 10(4):e0220622. PubMed ID: 35916524
[TBL] [Abstract][Full Text] [Related]
16. SHV Hyperproduction as a Mechanism for Piperacillin-Tazobactam Resistance in Extended-Spectrum Cephalosporin-Susceptible
Han MS; Park KS; Jeon JH; Lee JK; Lee JH; Choi EH; Lee SH
Microb Drug Resist; 2020 Apr; 26(4):334-340. PubMed ID: 31651221
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamics of Piperacillin-Tazobactam/Amikacin Combination versus Meropenem against Extended-Spectrum β-Lactamase-Producing Escherichia coli in a Hollow Fiber Infection Model.
Islam K; Sime FB; Wallis SC; Bauer MJ; Naicker S; Won H; Zowawi HM; Choudhury MA; Shirin T; Habib ZH; Harris PNA; Flora MS; Roberts JA
Antimicrob Agents Chemother; 2022 Sep; 66(9):e0016222. PubMed ID: 35924928
[TBL] [Abstract][Full Text] [Related]
18. Exploring the genetic mechanisms underlying amoxicillin-clavulanate resistance in waterborne Escherichia coli.
Singh NS; Singhal N; Kumar M; Virdi JS
Infect Genet Evol; 2021 Jun; 90():104767. PubMed ID: 33581330
[TBL] [Abstract][Full Text] [Related]
19. Exploring the effectiveness of tazobactam against ceftazidime resistant Escherichia coli: insights from the comparison between susceptibility testing and beta-lactamase inhibition.
Bethel CR; Hujer AM; Helfand MS; Bonomo RA
FEMS Microbiol Lett; 2004 May; 234(1):99-103. PubMed ID: 15109726
[TBL] [Abstract][Full Text] [Related]
20. The impact of the increased use of piperacillin/tazobactam on the selection of antibiotic resistance among invasive Escherichia coli and Klebsiella pneumoniae isolates.
Lee J; Oh CE; Choi EH; Lee HJ
Int J Infect Dis; 2013 Aug; 17(8):e638-43. PubMed ID: 23523562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
